Search details
1.
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
Nature
; 539(7629): 443-447, 2016 11 17.
Article
in English
| MEDLINE | ID: mdl-27828943
2.
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Blood
; 131(8): 888-898, 2018 02 22.
Article
in English
| MEDLINE | ID: mdl-29233821
3.
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Am J Hematol
; 93(11): 1311-1317, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30033575
4.
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Am J Hematol
; 93(11): 1318-1326, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30094870
5.
The mutation spectrum revealed by paired genome sequences from a lung cancer patient.
Nature
; 465(7297): 473-7, 2010 May 27.
Article
in English
| MEDLINE | ID: mdl-20505728
6.
Diverse somatic mutation patterns and pathway alterations in human cancers.
Nature
; 466(7308): 869-73, 2010 Aug 12.
Article
in English
| MEDLINE | ID: mdl-20668451
7.
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.
Genome Res
; 22(4): 593-601, 2012 Apr.
Article
in English
| MEDLINE | ID: mdl-22267523
8.
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.
Genome Res
; 22(12): 2315-27, 2012 Dec.
Article
in English
| MEDLINE | ID: mdl-23033341
9.
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
Proc Natl Acad Sci U S A
; 109(47): 19368-73, 2012 Nov 20.
Article
in English
| MEDLINE | ID: mdl-23134728
10.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Breast Cancer Res Treat
; 138(1): 99-108, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-23420271
11.
Cancer genetics and drug discovery in the zebrafish.
Nat Rev Cancer
; 3(7): 533-9, 2003 Jul.
Article
in English
| MEDLINE | ID: mdl-12835673
12.
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Cancer Invest
; 30(10): 727-31, 2012 Dec.
Article
in English
| MEDLINE | ID: mdl-23061802
13.
Zebrafish as a cancer model system.
Cancer Cell
; 1(3): 229-31, 2002 Apr.
Article
in English
| MEDLINE | ID: mdl-12086858
14.
Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Mol Cancer Res
; 7(4): 511-22, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19372580
15.
Construction and application of a zebrafish array comparative genomic hybridization platform.
Genes Chromosomes Cancer
; 48(2): 155-70, 2009 Feb.
Article
in English
| MEDLINE | ID: mdl-18973135
16.
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Clin Cancer Res
; 14(23): 7733-40, 2008 Dec 01.
Article
in English
| MEDLINE | ID: mdl-19047100
17.
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
Cancer Res
; 66(2): 999-1006, 2006 Jan 15.
Article
in English
| MEDLINE | ID: mdl-16424035
18.
Regulation of ERK3/MAPK6 expression by BRAF.
Int J Oncol
; 29(4): 839-49, 2006 Oct.
Article
in English
| MEDLINE | ID: mdl-16964379
19.
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Clin Cancer Res
; 21(9): 2065-74, 2015 May 01.
Article
in English
| MEDLINE | ID: mdl-25649019
20.
Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass.
Cell Rep
; 12(3): 495-510, 2015 Jul 21.
Article
in English
| MEDLINE | ID: mdl-26166562